Investment
Features
FeesSafety
Academy
More
Pluang+

Compare KraneShares Electric Vehicles and Future Mobility (KARS) vs Merck & Co., Inc. (MRK) Price & Performance

KraneShares Electric Vehicles and Future MobilityTrade
Merck & Co., Inc.Trade

Price performance (Past 24H)

Key statistics

KraneShares Electric Vehicles and Future Mobility vs Merck & Co., Inc. — how do they compare? KraneShares Electric Vehicles and Future Mobility trades at $27.56 (market cap $74.06M), while Merck & Co., Inc. trades at $142.38 (market cap $352.29B). The key difference: Merck & Co., Inc. is far larger — about 4756.8× KraneShares Electric Vehicles and Future Mobility's market cap, and Merck & Co., Inc. pays a 2.38% dividend while KraneShares Electric Vehicles and Future Mobility pays none. Which is the better fit depends on your goals — on Pluang, investors hold KraneShares Electric Vehicles and Future Mobility for 46 Days and Merck & Co., Inc. for 98 Days on average.

KARSMRK
Market Cap
$74.06M$352.29B
Volume
2,5466,348,796
Sector
Sector/ThematicHealth
52-Week High
$38.01$156.43
52-Week Low
$27.25$82.49
Typical Hold Time
46 Days98 Days
Enterprise Value
—$399.05B
Dividend Yield
—2.38%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

KraneShares Electric Vehicles and Future Mobility

No Aura AI signal available yet.

Merck & Co., Inc.

Merck (MRK) trades at $142.40, up 0.33% on the day, with a bearish technical signal but strong analyst support. The company reported revenue of $65.0B in 2025 with a net income margin of 28.07%, though 2026 projections show a sharp decline to 4.76%. Recent acquisition activity includes the tender offer for Terns Pharmaceuticals to bolster its oncology pipeline, while cash flow trends indicate significant investing outflows in 2026.

The outlook is mixed: robust fundamentals and a consensus price target of $159.59 suggest upside, but high valuation ratios (P/E 114.23) and projected earnings volatility pose risks. Investors should weigh strong institutional buying against technical weakness and competitive pressures in the pharma sector.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

KARS

No sentiment data available yet.

MRK
18% Buy82% Sell
Avg holding period · 98 Days

Top news

Latest headlines on both assets

About KraneShares Electric Vehicles and Future Mobility

KARS invests in the global electric vehicle ecosystem and future mobility. It tracks the Bloomberg Electric Vehicles Index, providing exposure to EV manufacturers, battery technology, and lithium miners like Tesla, BYD, and Albemarle.

Read more on KARS →

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

Read more on MRK →